Alzheimer's Disease

'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update

Cannabis-Based Dronabinol Could Transform Alzheimer's Care, New Study Finds

Shark Tank's Barbara Corcoran Reveals Her Struggle With Alzheimer's In Her Family

Cannabis-Based Dronabinol Could Transform Alzheimer's Care, New Study Finds

Shark Tank's Barbara Corcoran Reveals Her Struggle With Alzheimer's In Her Family

This Medical Stock Soared Over 80% In Pre-Market After Advancing Gene Therapy Program For ALS, Alzheimer's And Parkinson's Diseases

Eli Lilly Shares Gain After Drug-Maker Gets FDA's Nod For Early Alzheimer's Treatment

This Medical Stock Soared Over 80% In Pre-Market After Advancing Gene Therapy Program For ALS, Alzheimer's And Parkinson's Diseases

Eli Lilly Shares Gain After Drug-Maker Gets FDA's Nod For Early Alzheimer's Treatment

EXCLUSIVE: New Alzheimer's Treatment? Promising Cannabinoid Compound Shows Hope, InMed CEO Says

Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines

Alzheimer's Disease Recent News

Could CBD Revolutionize Alzheimer's Treatment? New Study Explores Its Neuroprotective Properties

Cannabidiol (CBD), a non-psychoactive compound found in the cannabis plant, has emerged as a potential therapeutic agent for Alzheimer's Disease. While research is still in the early stages, several studies have shown that CBD may help prevent and alleviate some of the disease’s symptoms.

Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others

Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a renewed interest in developing vaccines to combat this

Autism Therapy: Cannformatics Targets Metabolic Imbalances Using Machine Learning

Cannformatics, an early-stage biotechnology company, has unveiled a groundbreaking advancement in the field of medical cannabis treatment for Autism Spectrum Disorder (ASD).

THC-Based Alzheimer's Trial In Puerto Rico: IGC Pharma Targets Underrepresented Hispanic Communities

IGC Pharma, Inc.

FDA Approves Biogen's Alzheimer's Drug: Here Are Other Companies With Treatments In The Pipeline

The FDA fully approved Biogen Inc.’s (NASDAQ: BIIB) Alzheimer’s treatment Leqembi on Thursday, becoming the first Alzheimer’s antibody treatment to reach full approval.

Exclusive: FloraWorks Completes $2.25M Series-A Financing For Cannabinoid Research

FloraWorks, a cannabinoid therapeutics company specializing in rare and novel cannabinoids, has successfully completed a $2.25 million Series-A financing round. Leading this significant investment was life sciences venture capital firm, Bonaventure Equity LLC.

Roche's Another Alzheimer's Hopeful Flops In Phase 3 Program, Second Trial Setback Within Months

Study Shows Positive Results In Patients With Alzheimer's Disease And Agitation

SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system announced positive interim results from its Phase IIa trial of SCI-110 in patients with Alzheimer’s Disease

These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win

Alzheimer's Progression Slowed Down By Biogen's New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock

Biogen, Inc. (NASDAQ: BIIB) and Eisai Co. Ltd. (OTC: ESALY) announced late Tuesday positive results from a late-stage study of their Alzheimer’s treatment candidate.

EXCLUSIVE: Cognition Therapeutics Shares Biomarker Data From Alzheimer's Candidate

Cognition Therapeutics Inc (NASDAQ: CGTX) presented a proteomic analysis of clinical biomarker data from the SPARC study of CT1812 in mild-to-moderate Alzheimer's disease at the Alzheimer's Association International Conference.

AbbVie Dumps An Early-Alzheimer's Candidate Developing In Collaboration With Alector

Researchers Investigate New Treatment Pathways For Alzheimer's After Commercial Failure Of Biogen's Aduhelm

The commercial failure of Biogen Inc's (NASDAQ: BIIB) drug Aduhelm has put a new focus on the research into the causes of Alzheimer's disease.

Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug

New York Times Report Fresh Allegations On Cassava's Simufilam Alzheimer's Trials, Shares Fall

Cassava Sciences Inc (NASDAQ: SAVA) shares are shedding over 20% after

EXCLUSIVE: Longeveron Adds Miami Veterans Affairs Site To Its Ongoing Mid-Stage Alzheimer's Trial

Longeveron Inc (NASDAQ: LGVN) has announced a Cooperative Research and Development Agreement (CRADA) with the United States Department of Veterans Affairs (VA) to add Miami VA clinical site to its ongoing Phase 2 Alzheimer’s Disease (AD) trial.

Biogen's Alzheimer's Drug Aduhelm Medicare Coverage Restricted To Just Clinical Trials, CMS Finalizes

Centers for Medicare and Medicaid Services (CMS) finalized its decision to restrict coverage for Biogen Inc's (NASDAQ:&

EXCLUSIVE: Longeveron's Lomecel-B Data In Alzheimer's Disease Published In Medical Journal

Longeveron Inc (NASDAQ: LGVN) announced the publication of Phase 1 trial results of Lomecel-B on patients with mild Alzheimer's disease (AD) in the Alzheimer's & Dementia journal.

Biogen, Eisai Unveil New Data On Another Alzheimer's Candidate, Lecanemab

In the partnership that spawned aducanumab, Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) have

Biogen Shares Aduhelm Data In Alzheimer's Disease At 128 Weeks

Prothena Highlinghts New Preclinical Data For Alzheimer's, Parkinson's Vaccine Programs

Prothena Corporation plc (NASDAQ: PRTA)

Gain Therapeutics Posts Encouraging Preclinical Data From Parkinson's, Alzheimer's Programs

Biogen, Eisai Amend Their Alzheimer's Drug Marketing Pact